Affimed NV AFMDQ
Trading Information
- Previous Close Price
- $0.00
- Day Range
- $0.00–0.00
- 52-Week Range
- $0.00–0.05
- Bid/Ask
- $0.01 / $0.10
- Shares Outstanding
- 16.39M
- Market Cap
- $1,639.23
- Volume/Avg
- 541 / 4,054
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 78
- Website
- https://www.affimed.com
Valuation
|
Metric
|
AFMDQ
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
AFMDQ
|
|---|---|
Quick Ratio | 1.76 |
Current Ratio | 1.93 |
Interest Coverage | −51.50 |
Quick Ratio
AFMDQ
Profitability
|
Metric
|
AFMDQ
|
|---|---|
Return on Assets (Normalized) | −88.25% |
Return on Equity (Normalized) | −152.41% |
Return on Invested Capital (Normalized) | −110.34% |
Return on Assets
AFMDQ
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|nV^K$W | LOCK|!L&> | $133B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|Ts@!T!z | LOCK|b%?Vr | $83B | |||
| argenx SE ADR
ARGX
| LOCK|h@<&DlT | LOCK|g<K | $55B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|!K%vtks | LOCK|?XMX | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|l<lmjH | LOCK|qJ% | $42B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|kt^F%$T | LOCK|j!Pk | $29B | |||
| Incyte Corp
INCY
| LOCK|qN?Wq% | LOCK|?G | $25B | |||
| Moderna Inc
MRNA
| LOCK|>h?zGb | LOCK|ns | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|><BKhf | LOCK|TC | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|VpRS>&# | LOCK|>&x | $17B |
United States